Skip to main content
Arthur Bertolino, MD, Dermatology, Holland, MI

ArthurPBertolinoMD

Dermatology Holland, MI

Physician

Are you Dr. Bertolino?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 58 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    6362 144th Ave
    Holland, MI 49423
    Phone+1 201-965-9573

Summary

  • Dr. Arthur Bertolino, MD is a board certified dermatologist in Holland, Michigan. He is currently licensed to practice medicine in Michigan, Massachusetts, and Ohio.

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Dermatology, 1983 - 1985
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1982 - 1983
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Dermatology, 1981 - 1982
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineInternship, Transitional Year, 1980 - 1981
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1980

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2003 - 2026
  • NJ State Medical License
    NJ State Medical License 1987 - 2019
  • NY State Medical License
    NY State Medical License 1981 - 2019
  • MD State Medical License
    MD State Medical License 1980 - 2018
  • MA State Medical License
    MA State Medical License 2003 - 2017
  • OH State Medical License
    OH State Medical License 2001 - 2017
  • American Board of Dermatology Dermatology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Innovation Pharmaceuticals Partnering Provides Momentum for Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient Need
    Innovation Pharmaceuticals Partnering Provides Momentum for Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient NeedOctober 14th, 2019
  • Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. For the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis
    Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. For the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative ProctosigmoiditisJuly 22nd, 2019
  • Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6
    Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6May 29th, 2019
  • Join now to see all